ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
19 hedge funds and large institutions have $6.49M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2017 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
46% more funds holding
Funds holding: 13 → 19 (+6)
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
1.97% less ownership
Funds ownership: 17.56% → 15.59% (-2%)
17% less capital invested
Capital invested by funds: $7.84M → $6.49M (-$1.35M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
+$281K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$202K |
| 3 |
SG
StoneX Group
New York
|
+$57.8K |
| 4 |
RPG
Risk Paradigm Group
Austin,
Texas
|
+$49.3K |
| 5 |
Citigroup
New York
|
+$25.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$1.18M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$239K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$38.7K |
| 4 |
AG
Advisor Group
Phoenix,
Arizona
|
-$10.6K |
| 5 |
BL
BCWM LLC
Overland Park,
Kansas
|
-$7.63K |
CNCR Hedge Fund Activity: Q4 2017 in Review
19 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q4 2017, worth a combined $6.49M — down 17% from $7.84M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CNCR positions and 2 closed out — a net gain of 6 holders — while 4 added to existing stakes and 3 trimmed.
The largest buyer was LPL Financial, adding an estimated $281K. The largest seller was Jane Street, exiting entirely with an estimated $1.18M sold.
- 19 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q4 2017, up from 13 in Q3 2017.
- Funds reported $6.49M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q4 2017, down 17% quarter-over-quarter.
- 8 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q4 2017 and 2 closed out, a net change of +6 holders.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q4 2017 was LPL Financial, an estimated $281K added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q4 2017 was Jane Street, an estimated $1.18M sold.
Based on aggregated 13F filings for Q4 2017.